Drugs / WGc-0201
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07051187 | Sep 2026 → Sep 2027 expected | chronic hepatitis B virus infection | Jiyan Liu | Recruiting | No outcome recorded |
| Phase 1 | NCT07077369 | Aug 2025 → Dec 2027 expected | hepatocellular carcinoma | West China Hospital | Not yet recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | WGc-0201 | “WGc-0201 injection is an mRNA vaccine encoding the HBV-positive tumor antigen HBx.” NCT07051187 ↗ |
| Modality | Messenger RNA (mRNA) | “WGc-0201 injection is an mRNA vaccine” NCT07051187 ↗ |
| Route | Intramuscular | “administered by intramuscular route” NCT07051187 ↗ |